Entia Biosciences Study Achieves Improved Hair & Nail Health
Sherwood, Oregon / April 17, 2014 / Entia Biosciences, Inc. (OTCQB: ERGO), an authority on the clinical effects of oxidative stress and free radical reactions working in the areas of biotechnology and nutrigenomics, today announced the results of its pilot three-month clinical research study on the effectiveness of its GROH® Ergo Boost Hair and Scalp Conditioning Treatment and Daily Replenishing Supplements.
“We are excited and encouraged by the favorable results seen in our three-month pilot clinical research study on the effectiveness of our GROH® product lines,” said Devin Andres, President of Entia Biosciences Inc.’s Total Nutraceutical Solutions subsidiary. “Subjects reported not only a targeted decrease in hair loss, faster hair growth, increased thickness, less breakage, and increased volume, but a number of other healthy side effects including a natural increase in energy.”
Subjects were instructed to take GROH® supplements daily and apply the ErgoBoost Treatment to their hair and scalp. The subjects immediately reported softer, shinier, and smoother hair, regardless of baseline conditions. After six weeks, participants also reported a decrease in hair loss and an increase in thickness and volume. After 90 days, subjects reported decreased hair loss (88%), faster hair growth (75%), increased hair thickness (75%), decreased hair breakage (100%), and increased hair volume (93.5%).
In the study, blood samples were collected from subjects at baseline (September) and after three months (December) to assess levels of Vitamin D2 and D-total. Test results showed that the vitamin D2 levels doubled in greater than 85% of the subjects and all participants had a significant increase in total vitamin D. Additional findings from the study included improvements in skin appearance, nail strength, and nail growth, strongly suggestive that the nutrients in the GROH® product line also have the potential to improve overall health of the body. Most subjects also reported a natural increase in energy.
A separate study published in the Journal of Cosmetics by Dr. Irena Eris and faculty at the University of Warsaw showed that L-Ergothioneine may protect skin cells against UV-induced damage. The antioxidant was shown to reduce the oxidative stress on mtDNA from ultra-violet radiation by enhancing the level of reduced glutathione to protect against mtDNA “common deletion”. As a result, L-Ergothioneine could also become a potent skin care and anti-photoaging ingredient.
GROH® Daily Replenishing Supplements contain the unique bionutrients, L-Ergothioneine and Vitamin D2, which are found in high concentrations in specialty mushrooms and restore critical nutrient levels in the body. The company aims to position its GROH® product lines in the $50 billion hair and spa industry where many of the largest operators are seeking breakthrough products and services to differentiate their products in the competitive market.
Backed by scientific innovation and medical research, all GROH® products and services contain the powerful master antioxidant L-Ergothioneine, naturally amplified Vitamin D2, and other important micronutrients and co-factors found in plants and whole foods. These nutrients are unlocked, enhanced, and formulated into Ergo Boost Complex, which works with the body's biological systems to fulfill the everyday nutritional needs that our modern lifestyles fail to provide. With regular use, the GROH® Ergo Boost product line has the potential to balance cellular function and promote thicker, fuller hair and lashes, healthier skin, and increased nail strength and growth. For more information on the science behind this revolutionary new approach to health and beauty, please visit www.myGROH.com.
About Total Nutraceutical Solutions
Total Nutraceutical Solutions is the wholly owned consumer products subsidiary of Entia Biosciences (OTCQB: ERGO), Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. Entia Biosciences identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty, and agriculture. Founded in 2008 by Dr. Marvin S. Hausman MD, Entia has been researching the medical benefits of L-Ergothioneine and Vitamin D2 in the treatment of anemia, neurodegeneration, and other iron related disorders. Total Nutraceutical Solutions commercializes the non-medical applications for Entia's scientific discoveries and technology. For more information please visit http://www.entiabio.com/.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2013 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact Entia Biosciences at 971-228-0709
Click here to receive updates on Entia Biosciences.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx